Real world study from the CHAMP-HF registry comparing Entresto (sacubitril/valsartan) patients to patients not taking Entresto
Phase of Trial: Phase IV
Latest Information Update: 01 Sep 2018
Price : $35 *
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms CHAMP-HF
- Sponsors Novartis; Novartis Pharmaceuticals Corporation
- 04 Jun 2018 New trial record
- 28 May 2018 Interim data cut results (n=1095) presented in a Novartis media release.
- 28 May 2018 According to a Novartis media release, the interim data cut (n=1095) were presented as a part of a late-breaking session at the European Society of Cardiology Heart Failure (ESC-HF) Congress 2018.